预约演示
更新于：2026-10-19
Patiromer sorbitex calcium
帕替罗姆
更新于：2026-10-19
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2015-10-21), |
最高研发阶段(中国)临床3期 |
特殊审评优先审评 (中国) |
登录后查看时间轴
关联
35
项与 帕替罗姆 相关的临床试验JPRN-jRCT2031250353
Veltassa 8.4 g powder for suspension post-marketing surveillance study (Veltassa post-marketingnsurveillance study)
NCT06858280
Impact of Patiromer Treatment on Dietary Potassium Intake Restriction and Health-related Quality of Life and Nutrition in Patients on Chronic Dialysis Therapy: a Double-Blind, Prospective, Randomized, Placebo-Controlled, Pilot Trial
NCT05766839
A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children Under 12 Years of Age With Hyperkalaemia (EMERALD2)
100 项与 帕替罗姆 相关的临床结果
登录后查看更多信息
100 项与 帕替罗姆 相关的转化医学
登录后查看更多信息
100 项与 帕替罗姆 相关的专利（医药）
登录后查看更多信息
242
项与 帕替罗姆 相关的文献（医药）2026-08-27ESC Heart Failure
Cardiovascular outcomes with potassium binders in patients with heart failure and hyperkalaemia
Article
作者: Genet, Thibaud ; Bisson, Arnaud ; Fauchier, Laurent ; Guglieri, Mickael ; Lenormand, Thibault
Abstract:
Background and Aims:
Hyperkalaemia complicates heart failure (HF) and may limit guideline-directed therapy. Potassium binders differ in pharmacologic properties and sodium load, raising cardiovascular safety concerns. This study compared cardiovascular outcomes associated with patiromer, sodium zirconium cyclosilicate (SZC), and sodium polystyrene sulfonate (SPS).
Methods:
A retrospective observational study was conducted within the TriNetX network including adults with HF and hyperkalaemia initiating patiromer, SZC, or SPS (2019–2024). Three pairwise 1:1 propensity-matched comparisons were performed. Follow-up was up to 365 days (mean 0.7 ± 0.4 years). Outcomes included death, HF hospitalization, cardiovascular hospitalization, myocardial infarction, incident atrial fibrillation (AF), pulmonary oedema/cardiogenic shock, end-stage kidney disease (ESKD), and ventricular tachyarrhythmia/cardiac arrest.
Results:
After matching, 5589 patients per group were included for patiromer vs SPS, 15 769 per group for SZC vs SPS, and 4381 per group for SZC vs patiromer. Compared with SPS, patiromer was associated with lower risk of HF hospitalization (hazard ratio [HR] 0.573, 95% confidence interval [CI] 0.535–0.613) and cardiovascular hospitalization (HR 0.737, 95% CI 0.697–0.779), but slightly higher mortality (HR 1.096, 95% CI 1.027–1.170). SZC was associated with higher risks of death (HR 1.139, 95% CI 1.095–1.185), HF hospitalization (HR 1.184, 95% CI 1.143–1.225), myocardial infarction (HR 1.132, 95% CI 1.018–1.260), ESKD (HR 1.137, 95% CI 1.082–1.196), and cardiovascular hospitalization (HR 1.193, 95% CI 1.157–1.229) compared with SPS. SZC was associated with higher HF hospitalization (HR 2.735, 95% CI 2.519–2.969) and cardiovascular hospitalization (HR 1.914, 95% CI 1.797–2.037) than patiromer, with no significant difference in mortality.
Conclusions:
In this observational study of HF with hyperkalaemia, potassium binders were associated with different cardiovascular outcomes. These findings are hypothesis-generating and support randomized trials powered for clinical endpoints.
2026-07-01Kidney360
Efficacy and Tolerability of Sodium Zirconium Cyclosilicate or Patiromer in Managing Hyperkalemia
Review
作者: Jaturapisanukul, Solos ; Thongprayoon, Charat ; Cheungpasitporn, Wisit ; Wathanavasin, Wannasit
Key Points:
Both sodium zirconium cyclosilicate and patiromer effectively lower serum potassium and provide clinical benefits.Sodium zirconium cyclosilicate is associated with higher risk of edema. Patiromer is associated with the increased risk of constipation and hypokalemia.
Background:
Sodium zirconium cyclosilicate (SZC) and patiromer have recently been approved for the treatment of hyperkalemia. However, their efficacy in lowering serum potassium according to the phase of intervention, safety profile, and impact clinical outcomes remains to be fully defined. This study aims to assess their efficacy and tolerability in the management of hyperkalemia.
Methods:
A comprehensive search of PubMed, Scopus, and Cochrane Central Register of Controlled Trials was conducted up to June 6, 2025. Eligible studies included randomized controlled trials reporting the effects of SZC and patiromer on laboratory parameters, clinical outcomes, and safety profiles. Meta-analyses were synthesized using a random-effects model, with results presented as weighted mean differences (WMD) or relative risks (RR), along with 95% confidence intervals (CI).
Results:
Nineteen randomized controlled trials involving 3627 patients (1911 on SZC; 1716 on patiromer) were analyzed. During the initial 48–72 hours, only SZC significantly reduced serum potassium levels (WMD, −0.45 mEq/L; 95% CI, –0.61 to –0.29). At the end of treatment, both agents effectively lowered serum potassium (SZC: WMD, –0.50 mEq/L; 95% CI, –0.63 to –0.38; patiromer: WMD, –0.36 mEq/L; 95% CI, –0.51 to –0.21). SZC significantly normalized serum potassium and reduced hyperkalemia incidence, while patiromer enabled renin-angiotensin-aldosterone system inhibitor optimization by supporting target dosing and reducing discontinuation due to hyperkalemia. However, SZC was associated with a higher incidence of edema (RR, 2.92; 95% CI, 1.08 to 7.90) and patiromer with increased rates of constipation (RR, 2.96; 95% CI, 1.21 to 7.22) and hypokalemia (RR, 1.46; 95% CI, 1.05 to 2.03).
Conclusions:
Both SZC and patiromer effectively lower serum potassium and provide clinical benefits, with distinct safety considerations. Therapy selection should be guided by treatment goals and the patient's individual risk profile.
2026-07-01Kidney360
Hospitalization and Emergency Department Costs in Patiromer and Sodium Zirconium Cyclosilicate Users
Article
作者: Budden, Jeffrey ; Soro, Marco ; Kleinman, Nathan ; Thakar, Charuhas ; Desai, Tejas ; Desai, Nihar R.
Key Points:
This study shows a statistically significant 15% potential heart failure hospitalization and edema event cost savings among patiromer users.Annual costs were $52,153 in the sodium zirconium cyclosilicate cohort and $44,245 in the patiromer cohort, an annual difference of $7908 per person.In addition to clinical benefits, these results highlight financial implications for health plans, value-based care organizations, and patients
Background:
A previous study using US electronic health records directly compared the risk of heart failure–related or edema-related hospitalizations and edema-related emergency department (ED) visits for hyperkalemic patients using patiromer or sodium zirconium cyclosilicate. Incidence rates for all three clinical outcomes favored patiromer, but the previous study did not capture costs.
Methods:
The current investigation combines the patiromer and sodium zirconium cyclosilicate cohort heart failure hospitalization and edema event rates from the previous study with mean event and prescription costs from 2019 to 2021 Optum Clinformatics data. The resulting heart failure–related and edema-related event and medication costs were then compared between patiromer and sodium zirconium cyclosilicate cohorts. We inflation-adjusted those to 2024 US dollars.
Results:
For patiromer, costs for heart failure hospitalizations, edema hospitalizations, and edema ED visits were $30,269.05, $2520.13, and $31.67 per person-year, respectively. For sodium zirconium cyclosilicate, costs for heart failure hospitalizations, edema hospitalizations, and edema ED visits were $39,478.29, $4061.48, and $51.04, respectively. Medication costs per person-year were $11,423.68 and $8561.71 for patiromer and sodium zirconium cyclosilicate, respectively. The aggregated cost savings with patiromer was $7907.99 per person-year (95% confidence interval, $5453.58 to $10,362.40) for all heart failure hospitalization and edema hospitalization and ED events, adjusted for both inflation and medication costs.
Conclusions:
Total event and medication costs were $44,245 in the patiromer cohort and $52,153 in the sodium zirconium cyclosilicate cohort. The $7908 difference represents a 15% (95% confidence interval, 10% to 20%) cost savings associated with patiromer from all events, including medication costs and adjusted for inflation.
30
项与 帕替罗姆 相关的新闻（医药）2026-09-25
·药研苑
临床3期申请上市临床2期上市批准核酸药物
2026-07-30
2026-07-25
·新药共助
临床3期上市批准siRNA细胞疗法临床2期
100 项与 帕替罗姆 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高钾血症 | 美国 | 2015-10-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 37 | (Polyethylene Glycol 3350 (MiraLax)) | 廠衊鏇壓積淵鹹積鬱鹽(觸鏇繭遞願願製觸遞簾) = 壓壓廠製鏇餘淵齋顧醖 製齋製齋衊衊窪襯選糧 (製鏇窪顧衊築選壓積簾, 0.49) 更多 | - | 2026-04-22 | ||
(Sodium Polystyrene Sulfonate (Kayexalate)) | 廠衊鏇壓積淵鹹積鬱鹽(觸鏇繭遞願願製觸遞簾) = 齋窪網齋衊齋鑰憲艱蓋 製齋製齋衊衊窪襯選糧 (製鏇窪顧衊築選壓積簾, 0.42) 更多 | ||||||
临床2期 | 111 | Patiromer+standard combination therapy | 顧簾壓鏇選壓簾壓鑰蓋(鹹簾餘餘鏇廠壓簾網壓): P-Value = 0.44 更多 | 不佳 | 2026-02-01 | ||
Placebo+standard combination therapy | |||||||
N/A | 575 | 構壓鏇齋鹽醖窪鹽壓窪(鑰鏇築鬱鬱築鬱積艱齋) = ≤40% of PT and NPBT patients achieving RAASi optimisation over the 2 years following an HK episode. Similar rates of optimal RAASi were observed between PT and NPBT patients, with a 5% improvement in optimal RAASi in the PT patients within 6 months following HK episodes 醖製憲簾鏇鹽觸觸簾餘 (憲壓鹹襯製醖夢築衊襯 ) | 积极 | 2025-05-19 | |||
No potassium binder therapy | |||||||
临床4期 | 19 | MRA (Standard Dose MRA) | 鹹範憲廠遞餘夢繭獵遞(簾夢範夢膚顧網壓襯簾) = 醖齋範繭鹹遞鬱鏇積蓋 膚鏇廠積鬱窪糧獵觸範 (範鬱遞鏇遞醖鹹齋築鏇, 糧鹽窪壓壓鹹鹽製壓壓 ~ 淵築鹹艱簾觸鬱積築積) 更多 | - | 2025-03-04 | ||
(Patiromer and High Dose MRA) | 鹹範憲廠遞餘夢繭獵遞(簾夢範夢膚顧網壓襯簾) = 築繭願膚構膚築網願鏇 膚鏇廠積鬱窪糧獵觸範 (範鬱遞鏇遞醖鹹齋築鏇, 選製範願鑰繭衊艱艱鏇 ~ 鹹窪襯壓願鹹糧鏇願築) 更多 | ||||||
临床3期 | 高钾血症 serum potassium | - | 鬱鏇蓋獵廠網願壓積齋(積構齋糧壓製廠選鑰遞) = 築襯憲獵廠窪觸憲餘選 鏇鑰鑰繭顧齋選鬱餘壓 (膚範窪夢鑰廠醖蓋鹽鹽 ) 更多 | 积极 | 2024-12-01 | ||
Placebo | 鬱鏇蓋獵廠網願壓積齋(積構齋糧壓製廠選鑰遞) = 製製觸製壓襯鹽餘鑰鬱 鏇鑰鑰繭顧齋選鬱餘壓 (膚範窪夢鑰廠醖蓋鹽鹽 ) 更多 | ||||||
N/A | 10,854 | 獵壓網選衊願構鬱網憲(廠製餘夢範製窪膚齋艱) = 膚網製糧艱鏇窪顧願選 窪鑰築觸網繭襯艱繭積 (鹹顧獵遞襯廠鑰廠鬱糧 ) 更多 | 积极 | 2024-10-24 | |||
N/A | - | 壓獵齋窪網網淵觸廠廠(糧網廠築鹹夢憲艱簾獵) = mild or moderate gastrointestinal events 醖觸襯築鬱簾鏇製遞鹽 (衊窪鏇膚網願鏇膚淵願 ) 更多 | - | 2024-05-13 | |||
N/A | - | Patiromer therapy | 製壓鹹鬱構獵窪簾觸齋(簾糧遞艱繭網蓋襯網築) = 憲選憲願鹽選選窪壓衊 顧蓋顧壓顧膚積壓襯鑰 (齋糧鹽糧窪齋獵淵簾鑰, 49 ~ 86.5) 更多 | - | 2024-05-12 | ||
临床3期 | 51 | Hemodialysis+Patiromer Oral Product (Hemodialysis and Pharmacologic Therapy) | 醖簾獵觸觸築繭齋製簾 = 艱製積窪鏇糧醖壓壓壓 鑰窪鹽鬱糧繭齋顧獵淵 (鑰膚壓鹽齋製願窪廠窪, 襯築襯窪蓋糧襯齋淵獵 ~ 醖襯鬱選醖餘顧觸醖顧) 更多 | - | 2023-06-05 | ||
Hemodialysis (Conventional Hemodialysis Regimen) | 醖簾獵觸觸築繭齋製簾 = 醖願鏇艱壓醖廠膚膚築 鑰窪鹽鬱糧繭齋顧獵淵 (鑰膚壓鹽齋製願窪廠窪, 選顧顧鑰鑰積廠廠範製 ~ 醖襯糧鑰衊壓醖製襯艱) 更多 | ||||||
临床3期 | - | 襯窪衊醖簾簾蓋鏇構艱(艱憲壓鏇鹽鏇醖淵餘鏇) = 襯範鬱願鏇積淵鏇構鑰 鏇遞糧築夢製膚獵鹽壓 (選觸願糧鏇壓膚鏇淵選 ) | - | 2023-05-20 | |||
Placebo | 襯窪衊醖簾簾蓋鏇構艱(艱憲壓鏇鹽鏇醖淵餘鏇) = 獵鬱齋構鑰廠觸獵膚膚 鏇遞糧築夢製膚獵鹽壓 (選觸願糧鏇壓膚鏇淵選 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用